More FDA Discipline Review Letters Could Improve PDUFA, Firms Say
This article was originally published in The Tan Sheet
Pharma industry representatives urge changes to FDA program to increase application review transparency and communication between agency and NDA sponsors. Stakeholders spoke at a meeting for an interim assessment of enhanced review transparency and communication established under PDUFA V.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.